News

In the January 2023 episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, offer their perspective on the American Academy of Pediatric’s obesity guidance, the results of Nature Medicine study examining AID in type 2 diabetes study, and new data calling into question the appropriate target for time in range for people with types 2 diabetes.

Patients with mild infection are not at particular risk for severe, chronic outcomes from long Covid, according to new Israel data.

The research suggests additional glaucoma surgery was required more frequently after trabeculectomy than after Baerveldt glaucoma implant surgery.

A cross-sectional study showed cannabis ingestion has been the cause of 1 in every 3 pediatric poisoning hospitalizations in provinces that sell edibles.

Mattresses, toilet floors, and room floors were places where C difficile was commonly detected in areas inhabited by C difficile infection positive populations.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.

An overview of some of the biggest articles in the dermatology field covered this week, including new breakthroughs in research.

Circumpapillary structure measurements showed a dose-dependent increase with the induction of negative pressure.

Eyes with concurrent uveitis in a Swedish cohort had worse BCVA prior to and following cataract surgery, although visual improvement was greater compared to control eyes.

An interview segment featuring Lal’s experiences treating epidermolysis bullosa as well as his opinions on treatment and management.

The guidelines include advocating for more preventative care and changing how the disease is diagnosed.

An analysis of NHANES data from 1999-2018 details the progress made with regard to cholesterol management on a population level but also provides insight into areas where room for improvement still exists.

Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.

An interview with Karan Lal on his experiences treating patients facing the rare condition known as epidermolysis bullosa.

Dupilumab is currently the only treatment for eosinophilic esophagitis approved by the US Food and Drug Administration.

Based on 2021 data from NHATS, vision impairment is more prevalent among those who are older, Hispanic, non-White, less educated, and lower income.

“The fact that patients report substituting cannabis for pain medications so much underscores the need for research on the benefits and risk of using cannabis for chronic pain,” investigators stated.

Higher preoperative visual acuity in patients with dTRD was associated with higher vision after PPV, suggesting the importance of early intervention.

An FDA announcement on this topical gene therapy for DEB pushes back the PDUFA date to May of this year, accompanying a regulatory update.

A simulation study including both cardiologists and pulmonologists found providers failed to properly diagnose pulmonary hypertension more than 50% of the time.

Nearly half of patients treated with vonoprazan 10 mg and 20 mg achieved more 24-hour heartburn free days compared to participants treated by placebo.

Gut microbiota diversity was lower in below average responders, while 39.5% of participants had a serological response below the geometric mean.

Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.

A recent study demonstrated that a combined treatment of topical corticosteroids and lebrikizumab led to reduced atopic dermatitis severity compared to the non-lebrikizumab group.

At 12 months of the CAPLA trial, the addition of posterior wall isolation to pulmonary vein isolation led to no significant improvements in freedom from atrial arrhythmia.

Based on the identified biomarkers, it was possible to distinguish patients with a good predictive value for pain, sleep, and anxiety.

A secondary analysis of a cluster RCT indicated the Texas Sprouts intervention led to improvements in glucose control and reduced LDL-C in high-risk schoolchildren.

In her interview with HCPLive, Armstrong spoke on new data presented at Fall Clinical Dermatology on bimekizumab, deucravacitinib, and upadacitinib.